Patients using GLP-1 receptor agonists were also more likely to have microvascular complications and a history of depression
The glucose-dependent nature of insulin secretion with GLP-1 therapy represents a significant safety advantage
Drug Interactions and Warnings Evista should be used with caution if you have a history of blood clots or stroke
The threat of induced infringement liability has deterred some at-risk launches and strengthened the commercial value of method-of-use patents that would otherwise be easily designed around

In a post on X, Hims & Hers' chief executive, Andrew Dudum, said that the company will "continue to offer access to personalised treatments as allowed by law to meet patient needs," and will be "closely monitoring" the semaglutide supply chain, given that Novo Nordisk "stated two weeks ago that it would continue to have 'capacity limitations' and 'expected continued periodic supply constraints and related drug shortage notifications'." For its part, the FDA said it "has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved." The agency will continue to allow compounders to provide semaglutide to patients on a temporary basis "to avoid unnecessary disruption to patient treatment." State-licensed pharmacy or physician compounders can continue to do so until 22nd April, while outsourcing facilities have a deadline of 22nd May

Monitor Your Energy: Keep a journal of how you feel, noting changes in fatigue, skin clarity, and digestion